Citations

Clear

5 citation(s) found for "Large, Tim".

Bacterial and Fungal Communities Entombed Within Calcium Oxalate, Struvite, and Brushite Human Kidney Stones
Lange, Dirk , Dong, Yiran, Merkel, Annette, Krambeck, Amy E. , Rivera, Marcelino , Large, Tim , Weber, Joseph R. , Fouke, Bruce W. , Wilson, Elena M., Saw, Jessica J. , Sivaguru, Mayandi , Sanford, Robert A. , Fields, Christopher J. , Cregger, Melissa A. , Bruce, William J. , Lieske, John C. , Chia, Nicholas , Romero, Michael F.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 682-682

10.1681/asn.20203110s1682b Get It

Quick Sequential Organ Failure Assessment Score Is a Better Predictor of Septic Shock After Percutaneous Nephrolithotomy: A Secondary Analysis of Two Multicenter Prospective Trials
Gerrity, Jillian J., Berger, Jonathan , Hsi, Ryan S. , Stern, Karen , Chew, Ben H. , Nimmagadda, Naren , Kavoussi, Nicholas , Chen, Tony T., Krambeck, Amy E. , Large, Tim , Bechis, Seth K. , Monga, Manoj , Miller, Nicole L. , Lange, Dirk , Knudsen, Bodo E. , Sourial, Michael , Humphreys, Mitchell R. , Shah, Ojas , Abbott, Joel E. , Abedi, Garen , Sur, Roger L. , Chew, Ben H , Nimmagadda, Naren , Knudsen, Bodo , Abedi, Garen , Stern, Karen L , Hsi, Ryan , Miller, Nicole L , Gerrity, Jillian J., Friedlander, David Fallon

Mayo Clinic

Journal of Endourology | June 9, 2023 | Volume: 37 | Issue: 8 | Pages: 863-867

10.1089/end.2022.0677 | PMID 37294208 Get It

Multi-Institutional Prospective Randomized Control Trial of Novel Intracorporeal Lithotripters: ShockPulse-SE vs Trilogy Trial
Large, Tim , Nottingham, Charles U. , Brinkman, Ethan , Agarwal, Deepak , Ferrero, Andrea , Sourial, Michael , Stern, Karen , Rivera, Marcelino , Knudsen, Bodo E. , Humphreys, Mitchel, Krambeck, Amy E. , Nottingham, Charles , Knudsen, Bodo , Stern, Karen L

Mayo Clinic

Journal of Endourology | April 12, 2021 | Volume: 35 | Issue: 9 | Pages: 1326-1332

10.1089/end.2020.1097 | PMID 33843245 Get It

Introduction: Currently, there are multiple intracorporeal lithotripters available for use in percutaneous nephrolithotomy (PCNL). This study aimed to evaluate the efficiency of two novel lithotripters: Trilogy and ShockPulse-SE. Materials and Methods: This is a prospective multi-institutional randomized trial comparing outcomes of PCNL using two novel lithotripters between February 2019 and June 2020. The study assessed objective measures of stone clearance time, stone clearance rate, device malfunction, stone-free rates, and complications. Device assessment was provided through immediate postoperative survey by primary surgeons. Results: There were 100 standard PCNLs completed using either a Trilogy or ShockPulse-SE lithotrite. Using quantitative Stone Analysis Software to estimate stone volume, the mean stone volume was calculated at 4.18 ± 4.79 and 3.86 ± 3.43 cm 3 for the Trilogy and ShockPulse-SE groups, respectively. Stone clearance rates were found to be 1.22 ± 1.67 and 0.77 ± 0.68 cm 3 /min for Trilogy vs ShockPulse-SE ( p = 0.0542). When comparing Trilogy to ShockPulse-SE in a multivariate analysis, total operative room time (104.4 ± 48.2 minutes vs 121.1 ± 59.2 minutes p = 0.126), rates of secondary procedures (17.65% vs 40.81%, p = 0.005), and device malfunctions (1.96% vs 34.69%, p < 0.001) were less, respectively. There was no difference in final stone-free rates between devices. Conclusion: Both the Trilogy and ShockPulse-SE lithotripters are highly efficient at removing large renal stones. In this study, we noted differences between the two devices including fewer device malfunctions when Trilogy device was utilized. Clinical Trial ID number: NCT03959683
A Randomized Controlled Trial of Preoperative Prophylactic Antibiotics for Percutaneous Nephrolithotomy in Moderate to High Infectious Risk Population: A Report from the EDGE Consortium
Sur, Roger L. , Krambeck, Amy E. , Large, Tim , Bechis, Seth K. , Monga, Manoj , Hsi, Ryan S. , Miller, Nicole L. , Lange, Dirk , Knudsen, Bodo E. , Sourial, Michael , Humphreys, Mitchell R. , Stern, Karen , Shah, Ojas , Abbott, Joel E. , Abedi, Garen , Knudsen, Bodo, Stern, Karen L, Stern, Karen L , Hsi, Ryan , Friedlander, David Fallon , Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Urology | December 28, 2020 | Volume: 205 | Issue: 5 | Pages: 1379-1386

10.1097/ju.0000000000001582 | PMID 33369488 Get It

Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma.
Perbost, Régis, Turcan, Sarah, Danan, Corinne , Neelapu, Sattva S. , Jacobson, Caron A. , Lekakis, Lazaros J. , Chou, Justin , Xue, Allen , Rossi, John M. , Bot, Adrian , Galon, Jérôme , Scholler, Nathalie , Danan, Corinne, Locke, Frederick L. , Miklos, David B. , Lin, Yi , Ghobadi, Armin , Wang, Zixing

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 3022-3022

10.1200/jco.2020.38.15_suppl.3022 Get It

3022 Background: Axi-cel is a US and EU-approved autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for pts with relapsed/refractory large B cell lymphoma after ≥ 2 prior therapies. In ZUMA-1 (NCT02348216), the objective response rate was 83% (58% complete response rate; Locke et al. Lancet Oncol. 2019). T cell-related biology (Immunosign 21; Immunoscore) measured pretreatment in the tumor microenvironment (TME) was associated with response to axi-cel (Rossi et al. AACR 2018. #LB-016; Rossi et al. AACR 2019. #CT153). This expanded analysis characterized the pretreatment TME immune contexture and examined associations between immune cell subsets and response. Methods: In ZUMA-1, pts received axi-cel at a target dose of 2.0 × 106 CAR T cells/kg. Archival pretreatment tumor biopsy samples were analyzed by multiplex immunohistochemistry (Brightplex). Two panels were developed and applied to assess T cell (CD3, CD8, FoxP3, PD-1, LAG-3, TIM-3) and myeloid cell (CD11b, CD14, CD15, LOX1, S100A9, CD68) subsets (n = 14 total). The association between T cell and myeloid cell subset density, prespecified immune scores (Immunosign 21; Immunoscore), and objective response was evaluated. T test values were based on Brightplex analysis. Results: Pretreatment tumor biopsy samples from 18 pts were analyzed (14 objective responders and 4 nonresponders). The pretreatment TME comprised all major myeloid and T cell subsets, with diverse distribution across samples analyzed. The median TME density of monocytes (CD11b+ CD15− CD14+; 1215 cells/mm2) and macrophages (CD68+; 530 cells/mm2) was greater than that of the total CD8+ T cell subset (312 cells/mm2). The pretreatment Immunosign 21 and Immunoscore scores associated positively with the density of all major T cell subsets and some myeloid subsets. The density of activated CD8+ T cells (PD-1+ LAG-3+/− TIM-3−) was most significantly associated with clinical response versus other T cell subsets. The density of nonactivated CD8+ T cells (PD-1− LAG-3− TIM-3−) and exhausted CD8+ T cells (PD-1+ LAG-3+ TIM-3+) were not significantly associated with response. Additional characterization of the immune contexture and correlative analysis of cell subsets will be presented. Conclusions: These results suggest that a TME associated with increased density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells, measurable pretreatment, facilitates clinical response in pts post–axi-cel.